Stemergie: Back to the microscope

Academics and companies have toiled for years to identify markers that would enable discovery of drugs targeting cancer stem cells, which are believed to be responsible for recurrence. These efforts have failed to yield a reliable means of identifying the cells, but Stemergie Biotechnology S.A. believes it has done exactly that by going back to the microscope.

Using cancer stem cells it identified and isolated, the company has discovered small molecules that target glioma cancer stem cells and could be used in combination with standard of care to prevent recurrence...